摘要
AD患者脑内大量沉积的过渡态金属离子Cu(Ⅱ)能与β-淀粉样蛋白(Aβ)络合形成Aβ-Cu(Ⅱ)复合物,Aβ-Cu(Ⅱ)复合物在脑内聚集形成老年斑,进而对神经元造成损伤被认为是阿尔茨海默病致病机理的关键环节。用于阿尔茨海默病治疗的Cu(Ⅱ)螯合剂是一类能自由透过血脑屏障,络合AD患者脑内过量沉积的Cu(Ⅱ),从而溶解老年斑和缓解神经损伤的小分子活性物质。Cu(Ⅱ)螯合剂是近年来AD治疗策略的研究热点之一。文章综述了Cu(Ⅱ)诱导的Aβ集聚和氧化损伤毒性,总结了几种缓解Aβ-Cu(Ⅱ)复合物神经毒性的Cu(Ⅱ)螯合剂,并对Cu(Ⅱ)螯合剂作为AD治疗药物的研究前景作了展望。
Increased transition-state copper ion concentration has been found in the AD brain which implies that copper ion may participate in the pathophysiology of AD. Copper ion can bind with Aβ that form Aβ-Cu(Ⅱ) complex which aggregate in AD brains and cause neurotoxicity. Using Cu (Ⅱ) ligands as therapeutics has been proposed for treating AD. Chelator can bind with excessive Cu (Ⅱ) in AD brains and reduce neurotoxic of Aβ after cross brain blood barrier. This review discusses the aggregation of Aβ and oxidactive stress induced by copper ion, explores clioquinol, curcumin and their fuction as drugs in AD treatment.
出处
《生命的化学》
CAS
CSCD
北大核心
2009年第4期485-489,共5页
Chemistry of Life
基金
北京市属高等学校人才强教计划项目(PHR20090513)资助